Table 2A.
Primary endpoints by study arm—adjusted analysis.
| Visits | ||||||||
|---|---|---|---|---|---|---|---|---|
| Adjusted& means | Adjusted& difference in means | |||||||
| Markers | ||||||||
| T0 95% CI |
T6 95% CI |
T12 95% CI |
T0 95% CI p-Value |
T6 95% CI p-Value |
T12 95% CI p-Value |
p-Value* | ||
| CD4 count, cells/mm3 | ||||||||
| RCT arm | 0.297 | |||||||
| DTG/3TC | 800 (696, 905) | 818 (714, 922) | 754 (650, 858) | 0 | 0 | 0 | ||
| B/F/TAF | 943 (834, 1,053) | 905 (795, 1,014) | 906 (797, 1,016) | 143 (−13, 299) | 87 (−69, 243) | 152 (−4, 309) | ||
| 0.076 | 0.277 | 0.058 | ||||||
| CD8 count, cells/mm3 | ||||||||
| RCT arm | 0.380 | |||||||
| DTG/3TC | 908 (766, 1,050) | 931 (790, 1,072) | 853 (712, 995) | 0 | 0 | 0 | ||
| B/F/TAF | 938 (789, 1,087) | 898 (749, 1,047) | 880 (731, 1,029) | 30 (−183, 243) | −33 (−245, 180) | 27 (−186, 239) | ||
| 0.782 | 0.762 | 0.807 | ||||||
| CD4/CD8 ratio, units | ||||||||
| RCT arm | 0.731 | |||||||
| DTG/3TC | 1.0 (0.8, 1.1) | 1.0 (0.8, 1.2) | 1.0 (0.8, 1.2) | 0 | 0 | 0 | ||
| B/F/TAF | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.3) | 1.1 (1.0, 1.3) | 0.1 (−0.1, 0.4) | 0.1 (−0.2, 0.4) | 0.1 (−0.1, 0.4) | ||
| 0.414 | 0.451 | 0.299 | ||||||
RCT, randomized clinical trial; VL, viral load.
*F-test type 3 interaction p-value.
&Adjusted for age, nationality, AIDS, duration of HIV, duration of VL suppression, and CD4 count nadir.